Urgent

Choledocholithiasis — management

CBD stones · Gastroenterology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Common bile duct stones risk cholangitis and gallstone pancreatitis; risk-stratified using clinical, biochemical and imaging predictors to select ERCP, and most patients proceed to cholecystectomy to prevent recurrence.

Red flags

  • Fever, rigors and jaundice (cholangitis)
  • Hypotension/septic shock
  • Features of gallstone pancreatitis
  • Altered mental status (Reynolds pentad)

Assessment

Differential diagnosis

  • Ascending cholangitis
  • Gallstone pancreatitis
  • Malignant biliary obstruction
  • Mirizzi syndrome
  • Benign biliary stricture
  • Primary sclerosing cholangitis

Investigations

  • LFTs (cholestatic pattern, rising bilirubin/ALP)
  • FBC, CRP, amylase/lipase, coagulation
  • Transabdominal ultrasound (duct dilatation, stones)
  • MRCP or EUS for intermediate-probability stones
  • ERCP as therapeutic confirmation in high-probability cases

Management

  • Assess for cholangitis (fever, jaundice, RUQ pain) and pancreatitis — these change urgency
  • Stratify CBD stone probability using bilirubin, duct diameter on ultrasound and clinical features
  • High probability: proceed to ERCP with sphincterotomy and stone extraction
  • Intermediate probability: image further with MRCP or EUS before ERCP
  • Low probability: proceed to cholecystectomy with on-table cholangiogram or expectant management
  • Treat cholangitis with resuscitation, antibiotics and urgent biliary drainage
  • Clear the duct endoscopically; place a stent if the duct cannot be fully cleared at first attempt
  • Arrange laparoscopic cholecystectomy (ideally during the same admission) to prevent recurrence
  • Consider single-stage laparoscopic bile duct exploration where expertise exists
  • Correct coagulopathy before sphincterotomy and monitor for post-ERCP pancreatitis
  • Follow up to confirm LFT normalisation and completed cholecystectomy

Drugs & doses

Piperacillin-tazobactam 4.5 g IV three–four times daily (if cholangitis)
Co-amoxiclav 1.2 g IV three times daily (alternative)
Rectal diclofenac/indomethacin 100 mg PR at ERCP (post-ERCP pancreatitis prophylaxis)
Analgesia and IV fluids as required

Disposition

Admit for ERCP and early cholecystectomy; urgent biliary drainage if cholangitis.

Complications & pitfalls

  • Ascending cholangitis and sepsis
  • Gallstone pancreatitis
  • Post-ERCP pancreatitis, bleeding or perforation
  • Retained/recurrent stones
  • Biliary stricture

Exam pearls

  • A dilated CBD with a high/rising bilirubin on ultrasound makes stones highly likely — go straight to ERCP
  • Use MRCP or EUS to avoid unnecessary diagnostic ERCP in intermediate-risk patients
  • Same-admission cholecystectomy after ductal clearance reduces recurrent biliary events
  • Rectal NSAID at ERCP lowers the risk of post-ERCP pancreatitis

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.